Otsuka to Pay $865 Million For Europe and China Rights to Akebia's Anemia Treatment

Japan's Otsuka Pharma signed a $865 million deal to add non-US rights (including China) for a late-stage anemia drug from Boston's Akebia Therapeutics. Late in 2016, Otsuka entered a $1 billion agreement for US rights to vadadustat, an oral hypoxia-inducible factor stabilizer. The latest deal adds rights in Europe, China, Russia, Canada, Australia and the Middle East. Akebia will receive $73 million upfront and up to $792 million in development funding and milestone payments for the non-US rights. More details.... Share this with colleagues: // //